Two new drugs for obesity are getting close to approval

October 1997

Two new drugs for obesity are getting close to approval...sibutramine (Meridia, Knoll) and orlistat (Xenical, Roche).

Sibutramine is a serotonin AND norepinephrine reuptake inhibitor. It's similar to the antidepressant Effexor (venlafaxine).

Sibutramine reduces appetite and increases metabolism...but it can also raise blood pressure.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Diabetes give insulin to a diabetic who's allergic to latex
Obesity & Weight Loss The withdrawal of Redux (dexfenfluramine) and Pondimin (fenfluramine) leaves lots of unanswered questions
Obesity & Weight Loss Two new drugs for obesity are getting close to approval
Infectious Diseases recent cases of vancomycin-resistant Staph aureus
Women's Health Which PMS sufferers are most likely to benefit from an SSRI?
Women's Health FemPatch, a new Low-dose estrogen patch
Flomax (tamsulosin) for benign prostatic hyperplasia (BPH)
latest thinking is to treat HIV earlier and more aggressively
Patient compliance is EXTREMELY important with this new therapy.
Pediatrics leave their child's antibiotic suspension out of the refrigerator
Practice Transderm Scop, the popular behind-the-ear patch for motion sickness
reduce inappropriate use of antibiotics
combining St. John's wort with other drugs or certain foods
Depression when patients don't respond fully to their antidepressant
Diabetes Beta blockers are very beneficial for diabetics post-MI
Diabetes injecting Humalog AFTER meals